Disclosed are hydrogels polymerized with a biofunctional moiety, biodegradable and permanent, designed to be implantable in a mammalian body and intended to block or mitigate the formation of tissue adhesions. The hydrogels of the present invention are characterized by comprising four structural elements: a) a polymeric backbone which defines the overall polymeric morphology, b) linkage groups, c) side chains, and d) biofunctional end groups. The hydrophobicity of the various structural elements are chosen to reduce tissue adhesion and enhance the biofunctional aspect of the end groups. The morphology of these polymers are typically of high molecular weight and have shape to encourage entanglement. Useful structures include branching chains, comb or brush, and dendritic morphologies.

The group of inventions provides a biologically active additive and a method for preparing same. The biologically active additive is a micellar solution of an active substance in at least one emulsifier selected from the group comprising: polysorbate 20, polysorbate 80, polysorbate 20 and polysorbate 80, the emulsifier being adsorbed on amorphous mesoporous silicon dioxide nanoparticles having mesopore size from 0.2 to 1.8 nm by way of stirring in a disperser. The active substance may be selected from the group comprising: curcumin extract and rutin extract, dihydroquercetin extract, dihydroquercetin extract with quercetin extract, mixed tocopherol concentrate, cannabis oil with cannabidiol level up to 85%, cannabidiol isolate, cannabidiol isolate with mixed tocopherol concentrate, ADEK vitamin mixture concentrate, Sophora japonica extract, rosemary extract, cholecalciferol, thioctic acid, ferulic acid, resveratrol, resveratrol with ferulic acid, boswellia extract, betulin extract, icariin extract, chlorophyll extract, cannabidiol isolate with melatonin, cannabis oil having cannabidiol level up to 85% with passionflower extract, vardenafil, tadalafil, curcumin extract with soy lecithin, paclitaxel extract, collagen extract with soy lecithin. A method for preparing a biologically active additive comprises loading, into the disperser, an active substance in at least one emulsifier selected from the group comprising: polysorbate 20, polysorbate 80, polysorbate 20 and polysorbate 80, heating to a temperature of 80-90° C. while stirring continuously at from about 1000 rpm to about 2000 rpm, cooling to a temperature from below 60° C. to below 45° C., adding amorphous mesoporous silicon dioxide having a mesopore size from 0.2 to 1.8 nm, stirring at from about 1000 rpm to about 2000 rpm for about 0.5 h, followed by an increase in the stirring speed to 7000-9000 rpm until producing a homogeneous product in the form of a loose powder. The group of inventions provides improved bioavailability of the active substance.

The group of inventions provides a biologically active additive and a method for preparing same. The biologically active additive is a micellar solution of an active substance in at least one emulsifier selected from the group comprising: polysorbate 20, polysorbate 80, polysorbate 20 and polysorbate 80, the emulsifier being adsorbed on amorphous mesoporous silicon dioxide nanoparticles having mesopore size from 0.2 to 1.8 nm by way of stirring in a disperser. The active substance may be selected from the group comprising: curcumin extract and rutin extract, dihydroquercetin extract, dihydroquercetin extract with quercetin extract, mixed tocopherol concentrate, cannabis oil with cannabidiol level up to 85%, cannabidiol isolate, cannabidiol isolate with mixed tocopherol concentrate, ADEK vitamin mixture concentrate, Sophora japonica extract, rosemary extract, cholecalciferol, thioctic acid, ferulic acid, resveratrol, resveratrol with ferulic acid, boswellia extract, betulin extract, icariin extract, chlorophyll extract, cannabidiol isolate with melatonin, cannabis oil having cannabidiol level up to 85% with passionflower extract, vardenafil, tadalafil, curcumin extract with soy lecithin, paclitaxel extract, collagen extract with soy lecithin. A method for preparing a biologically active additive comprises loading, into the disperser, an active substance in at least one emulsifier selected from the group comprising: polysorbate 20, polysorbate 80, polysorbate 20 and polysorbate 80, heating to a temperature of 80-90° C. while stirring continuously at from about 1000 rpm to about 2000 rpm, cooling to a temperature from below 60° C. to below 45° C., adding amorphous mesoporous silicon dioxide having a mesopore size from 0.2 to 1.8 nm, stirring at from about 1000 rpm to about 2000 rpm for about 0.5 h, followed by an increase in the stirring speed to 7000-9000 rpm until producing a homogeneous product in the form of a loose powder. The group of inventions provides improved bioavailability of the active substance.

A nutraceutical composition including one or more sources of fiber, glutamine, one or more probiotics, one or more sources of omega-3, and one or more antioxidants, for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota. Also, a method for preventing and/or treating dysbiosis including a step of administering the nutraceutical composition to a patient in need thereof. Further, a three-part kit for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota.

A nutraceutical composition including one or more sources of fiber, glutamine, one or more probiotics, one or more sources of omega-3, and one or more antioxidants, for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota. Also, a method for preventing and/or treating dysbiosis including a step of administering the nutraceutical composition to a patient in need thereof. Further, a three-part kit for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota.

A method for treating a microbial infection, especially pneumonia, comprising administering an aqueous-ethanol extract of Thymus or Boswellia or a composition containing the extract. Aqueous-ethanol extracts of Thymus and/or Boswellia.

A method for treating a microbial infection, especially pneumonia, comprising administering an aqueous-ethanol extract of Thymus or Boswellia or a composition containing the extract. Aqueous-ethanol extracts of Thymus and/or Boswellia.

A nutraceutical dietary supplement formulation for the treatment of joint pain and discomfort may include astaxanthin powder; boswellia serrate gum resin extract; hyaluronic acid; undenatured type II (UC-II) collagen; eggshell membrane collagen powder; turmeric root extract; white willow bark extract; cayenne pepper extract; and Cat's Claw bark powder. The formulation may be formed into capsules for delivery to a user, wherein a therapeutically effective dosage of the formulation may be included in each capsule.

A nutraceutical dietary supplement formulation for the treatment of joint pain and discomfort may include astaxanthin powder; boswellia serrate gum resin extract; hyaluronic acid; undenatured type II (UC-II) collagen; eggshell membrane collagen powder; turmeric root extract; white willow bark extract; cayenne pepper extract; and Cat's Claw bark powder. The formulation may be formed into capsules for delivery to a user, wherein a therapeutically effective dosage of the formulation may be included in each capsule.

A nutraceutical dietary supplement formulation for the treatment of joint pain and discomfort may include astaxanthin powder; boswellia serrate gum resin extract; hyaluronic acid; undenatured type II (UC-II) collagen; eggshell membrane collagen powder; turmeric root extract; white willow bark extract; cayenne pepper extract; and Cat's Claw bark powder. The formulation may be formed into capsules for delivery to a user, wherein a therapeutically effective dosage of the formulation may be included in each capsule.